In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Anavex Life Sciences Corp.. Trade Record

NASDAQ:AVXL Anavex Life Sciences Corp. stock gains 18.48% Exit Sep 12, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart AVXL Aug 18, 2017, priceSeries
About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, a Phase 2a clinical trial for the treatment of Alzheimer's disease; and preclinical stage to treat Parkinson's disease. Its preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 and M1 muscarinic receptors to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.

Trade Information
Trade Type
LONG
ReliabilityScore™
88.20
Entry Date
Aug 18, 2017
Entry Price
3.93
Sell Date
Sep 12, 2017
Sell Price
4.66
Net Gain
18.48%
Hold Time
16 Trading Days